Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL701 and Pembrolizumab in Advanced Solid Cancers
NCT04171219Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of talabostat in malignant solid neoplasm and Recurrent malignant neoplasm, sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2020; status: terminated.
02
Drugs
talabostat
03
Conditions
malignant solid neoplasmRecurrent malignant neoplasm
Beyond the preview
Go deeper on NCT04171219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171219.